Search Results

· The companies will offer complementary services for developing and producing mRNA-based therapies. · WACKER provides pDNA/mRNA manufacturing and lipid formulation; RNAV8 offers an mRNA engineering platform. · Engineering non-coding regions of mRNA sequences enhances drug efficacy. · This collaboration positions WACKER and RNAV8 as premium mRNA service providers.

Joint press release by WACKER and Gearbox Biosciences · The partnership aims to co-develop technologies set to revolutionize manufacturing of plasmid DNA (pDNA), a critical raw material for advanced medicines · Focus on innovative workflows for antibiotic-free pDNA manufacturing and difficult-to-manufacture sequences · Joint solutions promise better scalability, efficiency and cost-effectiveness in production

· Additional research capacities set to accelerate growth in the Biosolutions division · A 1,500-square-meter laboratory and technical competence center and 700 square meters of office space present ideal conditions at the company’s central research location in Munich · The focus will be on research in manufacturing processes for biopharmaceuticals and ingredients for food and dietary supplements

After years of contraction, investors see biotech reentering a growth cycle driven by scientific progress, asset quality and renewed conviction in oncology, obesity and neuroscience innovation.

Biotech’s slump may finally be over in 2026. In interviews with BioSpace, Zymeworks’ CEO Ken Galbraith and Zai Lab’s President and COO Josh Smiley explain what’s fueling the comeback.

An inconsistent boom-and-bust cycle funding environment for early-stage biotech innovations and burdensome regulation threaten the U.S.’s half-century-long dominance in the biotech sector.

Nearly 100 biotechs went public amid the industry’s IPO frenzy in 2021, driven by an influx of pandemic-driven investments. But many of those companies have little to show investors.

The second half finished strong after two tumultuous years. What will 2026 bring for the biotech sector?

Pharmas will need to provide their latest stance on the Most Favored Nation drug pricing plans, while biotech finally gets a break after a few tough years.

Some 200 rare disease therapies are at risk of losing eligibility for a pediatric priority review voucher, a recent analysis by the Rare Disease Company Coalition shows. That could mean $4 billion in missed revenue for already cash-strapped biotechs.